TLR2 and neoplasm: In addition, we also demonstrated that lipoE7m combined with PSCpG could synergistically trigger the TLR2 and TLR9 pathways to decrease tumor immunosuppressive cells, including Tregs and MDSCs, to enhance the therapeutic effect of lipoimmunogens [12].